Telix Pharmaceuticals Limited (TLX) generates a steady flow of news related to its radiopharmaceutical pipeline, commercial portfolio, and global operations. As a biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, its announcements often highlight progress in oncology and rare disease programs, regulatory milestones, and commercial performance.
Recent Telix news has covered precision medicine portfolio updates, including Phase 3 data for TLX591-CDx (Illuccix) in China, regulatory interactions for TLX101-CDx (Pixclara) and TLX250-CDx (Zircaix) with the U.S. Food and Drug Administration, and inclusion of TLX250-CDx in international renal imaging guidelines. The company also reports on clinical collaborations, such as its agreement with Varian to explore combining Telix’s theranostic products with external beam radiation therapy.
Investors and clinicians following TLX news can expect updates on clinical trial milestones (for example, first patient dosed in the SOLACE trial for TLX090 or in the BiPASS Phase 3 trial for prostate cancer diagnosis), as well as information on reimbursement and market access developments. Telix has announced CMS Transitional Pass-Through status and a permanent HCPCS code for Gozellix in the United States, along with country-level approvals and launches for Illuccix in Europe and the United Kingdom.
Telix also issues news on financial performance and guidance, such as quarterly revenue updates and full-year revenue outlook, and on participation in major healthcare conferences where management presents the company’s pipeline and commercial strategy. For users tracking TLX, the news stream provides insight into how Telix advances its radiopharmaceutical products from clinical development through regulatory review and commercialization across multiple regions.
Telix (ASX/NASDAQ: TLX) announced a new independent analysis of Phase 3 ZIRCON data published in European Urology showing TLX250-Px (Zircaix, 89Zr-girentuximab) PET/CT was highly predictive of renal malignancy across subtypes. Reported metrics: PPV 98% (95% CI 96–99), sensitivity 82% (95% CI 82–90), and specificity 87% (95% CI 81–93). The exploratory analysis suggests utility beyond clear cell RCC (ccRCC), including potential roles in managing non-clear cell RCC, but these analyses were exploratory and were not the basis of the company’s BLA, which focuses on ccRCC detection.
Telix (ASX/NASDAQ: TLX) announced European validation and acceptance of its MAA for TLX101-Px (18F-FET) for glioma PET imaging. The application enters a 210-day active assessment covering major European markets. Telix said national approvals would follow after a positive Day-210 outcome.
The company noted no widely available commercial 18F-FET PET product exists in Europe and linked TLX101-Px to patient selection for its Phase 3 TLX101-Tx program.
Telix (ASX: TLX, NASDAQ: TLX) presented Phase 2 OPTIMAL-PSMA dosimetry data for TLX597-Tx at IPCS 2026 showing low salivary gland and kidney uptake and comparatively higher tumor uptake. Findings support dose intensification, potential improved tolerability, and initiation of a Phase 2 OPTIMAL-E study in earlier-stage mHSPC.
The randomized 120-patient OPTIMAL-PSMA trial used an intensified 8.5 GBq per-cycle regimen and compared safety, dosimetry and efficacy versus a standard schedule; TLX597-Tx and TLX591-Tx remain unapproved.
Telix (ASX: TLX, NASDAQ: TLX) will host an educational webinar on PSMA-targeted radionuclide therapy, focusing on Telix’s multi-product approach to prostate cancer. Speakers: Dr. David N. Cade and Professor Louise Emmett. Topic: OPTIMAL-PSMA2 data on TLX597-Tx (177Lu-DOTA-PSMA).
Webinar: AEST Thursday April 30, 2026 9:30 a.m.; EDT Wednesday April 29, 2026 7:30 p.m. Registration link available. TLX597-Tx has not received marketing authorization in any jurisdiction.
Telix (ASX: TLX, NASDAQ: TLX) announced that safety and tolerability data from Part 1 of the ProstACT Global Phase 3 study will be presented as a late-breaking oral presentation at ASCO 2026 on June 1, 2026.
Part 1 is a safety and dosimetry lead-in evaluating TLX591-Tx (177Lu-rosopatamab tetraxetan) plus standard of care in PSMA-positive mCRPC; abstract LBA5009, presenting author Pedro C. Barata, MD.
Telix (ASX: TLX, NASDAQ: TLX) dosed the first patient in the pivotal Phase 3 IPAX BrIGHT trial of TLX101-Tx for recurrent glioblastoma on April 14–15, 2026, at Austin Health in Melbourne.
The global, multicenter, open-label study compares TLX101-Tx plus lomustine versus lomustine alone, uses TLX101-Px PET for selection and response, and has regulatory approval in Australia, Austria, Belgium and the Netherlands.
Telix (ASX/NASDAQ: TLX) and Regeneron (NASDAQ: REGN) entered a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies on a 50/50 cost and profit-sharing basis. Telix receives US$40 million upfront for four initial programs and may earn up to US$2.1 billion in milestones plus low double-digit royalties. The deal covers multiple solid tumor antibody targets, potential radio-diagnostics for patient selection, and options to expand programs and commercialization roles.
Telix (TLX) announced that the FDA accepted its resubmitted NDA for TLX101-Px (Pixclara®, 18F-FET) for imaging glioma and set a PDUFA goal date of September 11, 2026. The agent has FDA Orphan Drug and Fast Track designations and is recommended in international guidelines for glioma imaging.
Telix said TLX101-Px aims to help distinguish tumor progression from treatment-related changes; FY2026 guidance excludes any revenue from TLX101-Px.
Telix (ASX/NASDAQ: TLX) announced two Non-Executive Director appointments effective May 11, 2026: Maria Rivas, MD, and William (Bill) Jellison, as part of Board expansion and succession planning. The hires add U.S. public company governance, late-stage clinical and commercial leadership, and corporate finance oversight to the Board.
The company said the appointments complement a recent director addition and support Telix’s evolution as a dual-listed, global commercial-stage biopharmaceutical company.
Telix (TLX) reported Q1 2026 group revenue of US$230 million, up 24% year-over-year and 11% sequentially, driven by Precision Medicine sales. The company reaffirmed FY2026 revenue guidance of US$950–970 million and R&D guidance of US$200–240 million.
Key clinical updates: ProstACT Part 1 met safety and dosimetry goals; NDA/MAA submissions and regulatory interactions progressed for multiple candidates across the U.S., Europe and China.